13.09.2011 • NewsNovartisAlconJoseph Jiminez

Novartis Expects Annual Cost Synergies of $350 Million From Alcon Integration

Novartis Tuesday said it now expects the integration of Alcon as an eye care segment to create annual cost synergies of $350 million by 2013. In January 2010, on acquiring a 77% majority stake in Alcon from Nestle, Novartis had estimated generating annual pre-tax cost synergies of approximately $200 million "within three years".

Updating on Alcon's performance, the company noted that both sales and core operating income had registered double-digit growth in the last 18 months.

Novartis's Chief Executive Officer Joseph Jimenez commented "This transaction was about long-term growth and not just cost synergies. We believe that Alcon has significant growth potential by leveraging the Novartis expertise in research, market access, and reimbursement, among others."

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.